The Neurodeath Associated Unit belonging to the University of Castilla-La Mancha and the BioFarma group of the CIMUS of the University of Santiago de Compostela are collaborating in the screening of the pharmacological effect of certain nanoparticles, based on carbohydrates, on the activity of certain intracellular molecules.
The purpose of this study is to rule out its toxicity and assess its progression towards in vivo studies to advance in the preclinical phase of development of a possible therapy against glioblastoma, a brain tumour for which there is currently no effective treatment.
The data obtained in this study indicate that the nanoparticles studied do not significantly affect the enzymatic activity of various kinases or that of several types of cytochrome P450, enzymes responsible for detoxifying drugs. They also do not appear to affect the ionic currents of excitable cells, as they do not modify the membrane potential of these cells.
Taken together, the data suggest that these nanoparticles are non-toxic and could be effective transporters of drugs and genetic material for the treatment of various diseases, including glioblastoma.
This collaboration is part of Line of Action 3: “Platform for drug screening and analysis of drug-target interactions” of the Biotechnology Applied to Health project of the Complementary Plans entitled: “Development of tools for diagnosis, prognosis and advanced or targeted therapies in personalized medicine” financed by funds from the European Union’s Recovery, Transformation and Resilience Plan.
